ERBB2 and neoplasm: Whereas trastuzumab binds to the extracellular domain of HER2 and inhibits ligand-independent signaling, pertuzumab prevents dimerization of HER2 with other family proteins and, thus, downstream signaling processes associated with tumor growth and progression [3–5].